Icosapent ethyl
A prescription medicine, sold as Vascepa, that is an ethyl ester of eicosapentaenoic acid (EPA), an omega-3 fatty acid. The US label lists it for lowering very high triglycerides in adults, and, added to a statin, for lowering the risk of heart attack, stroke and some other events in adults with raised triglycerides and either established cardiovascular disease or diabetes plus other risk factors. The label warns of a higher risk of atrial fibrillation or atrial flutter needing hospital care, and of bleeding.
Also called Vascepa
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 1304974. NDA202057, with an original submission dated 2012-07-26 in the openFDA record. The evidence recorded here is the Amarin label and the FDA record only; this record reads no outcome trial.
Trials at a glance
The figures count the 4 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.
- Trials
- 4
- Phase 3 or 4
- 2
- Recruiting
- 0
- Regulatory decisions
- 0
| Phase | Not yet recruiting | Active, not recruiting | Completed | Terminated | All statuses |
|---|---|---|---|---|---|
| Phase 2 | 0 | 1 | 1 | 0 | 2 |
| Phase 4 | 1 | 0 | 0 | 1 | 2 |
| All phases | 1 | 1 | 1 | 1 | 4 |
Conditions these trials study
- Dyslipidemia
- High triglycerides
- Aortic stenosis
- Atherosclerosis
- Coronary artery disease
- Heart valve disease
Sponsors with the most trials
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- China National Center for Cardiovascular Diseases
- Kaiser Permanente
- Matinas BioPharma Nanotechnologies, Inc.
About this drug
- Level
- Substance
- Mechanism
- The label says studies suggest that EPA reduces liver production or release of very low-density lipoprotein triglycerides and enhances triglyceride clearance from circulating VLDL particles. It says the mechanisms behind fewer cardiovascular events are not completely understood.
Claims and evidence
Context Adults with raised triglycerides, as the US Vascepa label describes them
- Recipient
- Adult
- Population
- Adult patients named in the indications of the US label for Vascepa: adults with elevated triglycerides and established cardiovascular disease or diabetes plus other risk factors, and adults with severe hypertriglyceridemia.
- Care setting
- Prescription medicine; the label adds the medicine to statin treatment or to diet, as stated in the indications
- Geography
- United States (FDA label)
- Life stage
- Adults; the label states adult patients
- Follow-up
- Not applicable (label text and a regulatory record)
Eligibility: inclusion criteria not stated; exclusion criteria not stated
- Included
- None stated
- Excluded
- None stated
The openFDA Drugs@FDA record for NDA202057 lists Vascepa, from AMARIN PHARMS, with an original submission (ORIG 1) in status AP (approved) dated 26 July 2012.
Applies to Adult Adults with raised triglycerides, as the US Vascepa label describes them
- Certainty method
- Not assessed
- Limitations
- An openFDA record, which openFDA says is unvalidated. It gives dates as compact numbers and does not state the indication approved in 2012; the label indications above are the current ones.
- Last checked
- 2026-10-30
- Next evidence check due
- Not scheduled
Sources and citations (2)
-
Supports FDA New Drug Application NDA202057: Vascepa (openFDA drugsfda record)
- Locator
- results[0].submissions[16]
- How it applies
- Original submission in the FDA record.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
41292867e3d790ed006a0ecfafa198151a08bf8d01aee67bc6385f643593a81f- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication unless noted, as the openFDA terms page states (fetched 2026-10-30, sha256 b11f712bfb11d03319675fc04e6948133a83c57aa2913b7f18d3677d0209f723, hash only). The raw record is committed in the atlas repository.
-
Supports FDA New Drug Application NDA202057: Vascepa (openFDA drugsfda record)
- Locator
- results[0].sponsor_name
- How it applies
- Applicant name in the FDA record.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
41292867e3d790ed006a0ecfafa198151a08bf8d01aee67bc6385f643593a81f- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication unless noted, as the openFDA terms page states (fetched 2026-10-30, sha256 b11f712bfb11d03319675fc04e6948133a83c57aa2913b7f18d3677d0209f723, hash only). The raw record is committed in the atlas repository.
The US Vascepa label says Vascepa (icosapent ethyl) is indicated, as an add-on to statin treatment at the highest dose the patient can tolerate, to reduce the risk of myocardial infarction, stroke, coronary revascularization and unstable angina requiring hospitalization in adult patients with elevated triglyceride levels (150 mg/dL or higher) and established cardiovascular disease or diabetes mellitus and 2 or more additional risk factors for cardiovascular disease. It is also indicated, as an adjunct to diet, to reduce triglyceride levels in adult patients with severe (500 mg/dL or higher) hypertriglyceridemia. The label says the effect on the risk of pancreatitis in patients with severe hypertriglyceridemia has not been determined.
Applies to Adult Adults with raised triglycerides, as the US Vascepa label describes them
- Certainty method
- Not assessed
- Limitations
- These are indications as the label states them, in the label version dated 2026-03-23. They say what FDA has approved the medicine for, not how well it works for any person. The trial evidence behind the cardiovascular indication is not read in this atlas yet.
- Last checked
- 2026-10-30
- Next evidence check due
- Not scheduled
Sources and citations (1)
-
Supports Vascepa drug label (openFDA record, set id 9c1a2828-1583-4414-ab22-a60480e8e508)
- Locator
- results[0].indications_and_usage[0]
- How it applies
- Label indications and limitations of use.
- Retrieved
- Source effective date
- 2026-03-23
- Source state
- Current
- Version fingerprint
12fe4482da2226bca5532a6f564670e78bc340e93b515177b8741bd0a6f5aebd- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication unless noted (https://open.fda.gov/terms/, fetched 2026-10-30, sha256 b11f712bfb11d03319675fc04e6948133a83c57aa2913b7f18d3677d0209f723, hash only). The label text is the manufacturer's labeling as FDA publishes it; check the openFDA documentation for a not-in-the-public-domain warning before quoting beyond short passages. The raw file is committed in the atlas repository.
The US Vascepa label says Vascepa is associated with an increased risk of atrial fibrillation or atrial flutter requiring hospitalization, and with an increased risk of bleeding.
Applies to Adult Adults with raised triglycerides, as the US Vascepa label describes them
- Certainty method
- Not assessed
- Limitations
- Warnings as the label states them, in the label version dated 2026-03-23. The label gives event counts from one trial; this atlas does not repeat them and has not read the trial.
- Last checked
- 2026-10-30
- Next evidence check due
- Not scheduled
Sources and citations (1)
-
Supports Vascepa drug label (openFDA record, set id 9c1a2828-1583-4414-ab22-a60480e8e508)
- Locator
- results[0].warnings_and_cautions[0]
- How it applies
- Label warnings and precautions, sections 5.1 and 5.3.
- Retrieved
- Source effective date
- 2026-03-23
- Source state
- Current
- Version fingerprint
12fe4482da2226bca5532a6f564670e78bc340e93b515177b8741bd0a6f5aebd- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication unless noted (https://open.fda.gov/terms/, fetched 2026-10-30, sha256 b11f712bfb11d03319675fc04e6948133a83c57aa2913b7f18d3677d0209f723, hash only). The label text is the manufacturer's labeling as FDA publishes it; check the openFDA documentation for a not-in-the-public-domain warning before quoting beyond short passages. The raw file is committed in the atlas repository.
FDA label
Assembled by a program from the openFDA drug label dataset, retrieved 8 November 2026, for the products that contain this drug: the label of the application holder or its company group, never a repackager's. Data provided by the U.S. Food and Drug Administration (open.fda.gov). The label is a manufacturer's submission that FDA has not verified, and the label on the product may differ. 1 label below.
VASCEPA
- Application
- NDA202057
- Labeler
- Amarin Pharma Inc.
- Label version
- Version 21, effective
- Label set id
9c1a2828-1583-4414-ab22-a60480e8e508- Boxed warning
- No boxed warning
- Sections the label has
- Indications and usage Contraindications Warnings and cautions Adverse reactions Drug interactions Use in specific populations Pregnancy Pediatric use Geriatric use Clinical pharmacology Clinical studies
FDA decisions timeline
The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact US label: indicated to lower severe hypertriglyceridemia and, with a statin, cardiovascular risk in adults with raised triglycerides: High triglycerides
Applies to Adult Adults with raised triglycerides, as the US Vascepa label describes them
The US Vascepa label says Vascepa (icosapent ethyl) is indicated, as an add-on to statin treatment at the highest dose the patient can tolerate, to reduce the risk of myocardial infarction, stroke, coronary revascularization and unstable angina requiring hospitalization in adult patients with elevated triglyceride levels (150 mg/dL or higher) and established cardiovascular disease or diabetes mellitus and 2 or more additional risk factors for cardiovascular disease. It is also indicated, as an adjunct to diet, to reduce triglyceride levels in adult patients with severe (500 mg/dL or higher) hypertriglyceridemia. The label says the effect on the risk of pancreatitis in patients with severe hypertriglyceridemia has not been determined.Limitations. These are indications as the label states them, in the label version dated 2026-03-23. They say what FDA has approved the medicine for, not how well it works for any person. The trial evidence behind the cardiovascular indication is not read in this atlas yet.
Registry records
Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry products 1
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 1 efficacy supplement approval on record.
Registry trials 4
Record details
- Record id
cardio:icosapent-ethyl- Content hash
319e7ae642de075482d2d07a486fe7995f79a4494b07e88818f113640e3fa83c